Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR by Maemondo Makoto, Inoue Akira, Kobayashi Kunihiko, Sugawara Shunichi, Oizumi Satoshi, Isobe Hiroshi, Gemma Akihiko, Harada Masao, Yoshizawa Hirohisa, Kinoshita Ichiro, Fujita Yuka, Okinaga Shoji, Hirano Haruto, Yoshimori Kozo, Harada Toshiyuki, Ogura Takashi, Ando Masahiro, Miyazawa Hitoshi, Tanaka Tomoaki, Saijo Yasuo, Hagiwara Koichi, Morita Satoshi, Nukiwa Toshihiro, North-East Japan Study Group in The New England journal of medicine (2010). PubMed

Abstract

Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of standard chemotherapy.

[ hide abstract ]

Discussed In Paper

Variant Annotations

Sign in to see variant annotations.